Linvoseltamab

Multiple Myeloma

Anne Louise Tølbøll SørensenPhase 4 / ApprovedActive

BB

66/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 70/ 100
Competitive Position: 59/ 100

Competitive context

497 Active assets in the Multiple Myeloma cohort.

Asset / Sponsor	Phase	Rating
FILGRASTIM Jonsson Comprehensive Cancer Center	Phase 4	BBB
Inno-206 University of Arkansas	Phase 3	BBB
Hyaluronidase fihj Massachusetts General Hospital	Phase 4	BBB
Busulphan M.D. Anderson Cancer Center	Phase 4	BBB
Filanesib PETHEMA Foundation	Phase 2	BBB

View all 50 →

Same molecule, other indications

Linvoseltamab is also rated in:

smoldering plasma cell myelomaDormant

BB

Indicative ·

66 / 100

Waldenstrom macroglobulinemiaDormant

BB

Indicative ·

65 / 100

monoclonal gammopathy of uncertain significanceDormant

CCC

Indicative ·

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.